- Cullinan Oncology Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Cullinan Oncology Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Cullinan Oncology Inc To Discuss About Licensing Agreement with Harbour Biomed TranscriptFeb 14, 2023
- Cullinan Oncology Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call TranscriptMay 12, 2022
- Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) TranscriptApr 13, 2022
- Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar TranscriptMar 28, 2022
- Cullinan Oncology Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Cullinan Oncology Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Cullinan Oncology Inc To Provide CLN-081 Clinical Update Webinar Call TranscriptDec 16, 2021
- Cullinan Oncology Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cullinan Oncology Inc Pearl Clinical Update Call TranscriptJun 04, 2021
Cullinan Oncology Inc at Barclays Global Healthcare Conference Transcript
Great. Thanks, everyone, for joining us this afternoon. It's my pleasure to introduce our next presenter from Cullinan Oncology, Nadim Ahmed, Chief Executive Officer. With that, I'll pass it to you, Nadim.
All right. So good afternoon, everyone. First live presentation in 2 years. So thanks for keeping the audience small, easing me back into it. So let me start out by saying a couple of things about Cullinan Oncology. So we're a company that's dedicated to creating new standards of care through a very unique approach to the drug discovery and development process.
Here are disclaimer slides, I will be making forward-looking statements. One thing you'll notice about our company is that we have a very broad and deep pipeline across multiple modalities, different indications, hematology, solid tumors and at various stages of development. And then the other thing I would add, when you look at each program, we have assets that, potentially at least, have the opportunity to be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)